Successful Treatment of Granuloma Faciale with Topical Tacrolimus: A Case Report and Immunohistochemical Study

Gen-ichi Tojo  Taku Fujimura  Yumi Kambayashi  Katsuko Kikuchi  Setsuya Aiba

Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan

Key Words
Granuloma faciale · Tacrolimus · Proinflammatory cytokine

Abstract
We report the case of a 55-year-old Japanese patient with granuloma faciale (GF) successfully treated with topical tacrolimus and describe the immunohistochemical study. Immunohistochemical staining revealed that the patient’s granuloma contained CD3⁺, CD4⁺, CD8⁺, CD68⁺ and CD163⁺ cells. Interestingly, these cells contained granulysin⁺ T cells and lacked Foxp3hi regulatory T cells. In addition, the macrophages were mainly CD163⁺, which suggested that the alternatively activated macrophage is one of the main components of GF. In summary, the present data shed light on the granuloma-composing cells and possible mechanisms in the treatment of GF with topical tacrolimus.

Introduction

Granuloma faciale (GF) is an uncommon disorder that mainly affects sun-exposed sites [1, 2]. It is characterized by reddish-brown plaque, and the histopathology is diagnostic. Clinically, the differential diagnosis includes discoid lupus erythematosus, sarcoidosis and Jessner’s lymphocytic infiltrate. The typical histopathological picture consists of a dense cellular infiltrate in the mid dermis with a grenz zone in the immediate subepidermis and with leukocytoclastic vasculitis [1, 2]. It is reported that the granuloma-composing cells are mainly eosinophils, lymphocytes, neutrophils and histiocytes, but the profiles of these lymphocytes and histiocytes have not been reported in detail. In the present report, we investigated the immunohistochemical profiles of the granuloma-composing cells, not only focusing on the effector T cells but
also on the immunosuppressive cells, such as regulatory T cells and skin-resident CD163+ macrophages.

**Case Report**

A 55-year-old Japanese man with a 2-year history of asymptomatic erythema on his nasal root visited our outpatient clinic. He had been treated with topical steroid and oral antihistamine for half a year without any improvement. On his initial visit, physical examination revealed dark, infiltrated erythema on his nasal root, 24 × 14 mm in size (fig. 1a). A biopsy specimen revealed a prominent cellular infiltrate in the mid dermis with a grenz zone (fig. 2a). The infiltrating cells were composed of eosinophils, lymphocytes, neutrophils and histiocytes. In the mid dermis, neutrophils were densely infiltrated around the vessels with deposition of fibrinoid (fig. 2b). The full blood count and biochemical profile were within normal ranges. From the above findings, we diagnosed GF. To further analyze the pathogenesis of GF, we performed immunohistochemical staining, which revealed that the granuloma-composing cells were CD3+ CD4+ (fig. 2c) and CD8+ (fig. 2d) in the inflammatory areas. In addition, TIA1+ and granulysin+ cells (fig. 2f) were scattered in areas of vasculitis. Few Foxp3high+ cells were detected (fig. 2e). Macrophages were mainly CD163+ (fig. 2h), and CD68+ cells were scattered (fig. 2g). We treated the patient with topical 0.1% tacrolimus twice a day and the erythema diminished after 2 months (fig. 1b). One year after stopping tacrolimus, there was no sign of relapsing erythematous plaque.

**Discussion**

In this report, we describe a case of GF successfully treated with topical tacrolimus and the immunohistochemical study. Our present data shed light on the granuloma-composing cells and possible mechanisms in the treatment of GF with topical tacrolimus.

GF is a localized craniofacial leukocytoclastic vasculitis that presents as recurrent reddish-brown plaques on the forehead, cheek and ears [2]. It was reported that mononuclear and plasma cells are dominant at the inflammatory areas of GF. In the present case, indeed, almost no Foxp3high+ regulatory T cells were detected, though numerous CD3+ CD4+ or CD8+ T cells were detected at granulomatous areas. Like psoriasis, the induced macrophages were mainly CD163+ macrophages, which were reported to produce proinflammatory cytokines such as IL-23 [3]. In addition, these infiltrating CD8+ cells contained granulysin+ cells, which were previously reported to contribute to severe cutaneous inflammatory disorders, such as toxic epidermal necrolysis [4]. In summary, one possible pathogenesis of GF might be associated with these proinflammatory circumstances.

Though previous reports suggested possible therapies for GF, such as intralesional corticosteroids, dapsone, cryosurgery, surgical excision and pulse dye laser [5–8], based on the above findings, we selected topical administration of 0.1% tacrolimus ointment. Topical tacrolimus has recently been shown to be an effective treatment for GF [9, 10]. Tacrolimus contains an immunosuppressive agent that inhibits T cell proliferation and production of several proinflammatory cytokines, such as IL-2, IL-4, IL-5, IFN-γ and TNF-α [11]. Interestingly, a previous report also suggested that topical administration of tacrolimus ointment increased the number of IL-10 producing cells and enhanced the production of TGF-β [11]. Regarding GF, Gauger et al. [12] previously reported that increased levels of IL-5 in the lesional skin might contribute to the
pathogenesis of GF. In our present case, indeed, the eruption diminished after 2 months of topical administration of 0.1% tacrolimus. In summary, topical administration of tacrolimus might suppress the proinflammatory cytokines and induce immunosuppressive cells in GF.

Fig. 1. Dark, infiltrated erythema on the nasal root, 24 × 14 mm in size, before (a) and after (b) the administration of topical tacrolimus.
Fig. 2. Prominent cellular infiltrate in the mid dermis with a grenz zone (a). Neutrophils were densely infiltrated around the vessels with deposition of fibrinoid (b). H&E staining, original magnification ×50 (a), ×400 (b). Paraffin-embedded tissue samples from the patient were stained as follows: the sections were developed with new fuchsin for CD4 (c), CD8 (d), Foxp3 (e), granulysin (f), CD68 (h), and CD163 (g). Original magnification ×100 (c, d, g, h), ×200 (f), ×400 (e).
References


